Please login to the form below

Not currently logged in
Email:
Password:

Anoro Ellipta

This page shows the latest Anoro Ellipta news and features for those working in and with pharma, biotech and healthcare.

Sovaldi pushes Gilead to the top of US pharma list

Sovaldi pushes Gilead to the top of US pharma list

The London-based firm has also failed to increase market share for its next-gen versions of Advair - namely Breo, Ellipta and Anoro Ellipta - which had combined sales last year of

Latest news

  • GSK's Anoro first LAMA/LABA approved for COPD in US GSK's Anoro first LAMA/LABA approved for COPD in US

    Important step towards eventually replacing Seretide/Advair sales. GlaxoSmithKline's (GSK) chronic obstructive pulmonary disease (COPD) portfolio received a significant boost yesterday with the US approval of combination product Anoro Ellipta.

  • GSK’s COPD drug Anoro under review in US GSK’s COPD drug Anoro under review in US

    FDA accepts new drug application for the LAMA/LABA combination. GlaxoSmithKline's (GSK) investigational respiratory treatment Anoro is under review by the FDA after the US regulator accepted its new drug ... The US submission follows Anoro's filing with

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Theravance hires BMS veteran Pasqualone Theravance hires BMS veteran Pasqualone

    Pasqualone joins Theravance as the company at a crucial time as its development deals with GlaxoSmithKline bears fruit with US approval of respiratory treatment Anoro Ellipta.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics